SEC For	m 4 FORM	4	UNITED S	STATE	S SI					NGE C	ЮММІ	SSION	·]
Section 16. Form 4 or Form 5 obligations may continue. See					Washington, D.C. 20549 NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										verage burden	3235-0287
1. Name and Address of Reporting Person* <u>DOYLE WILLIAM F</u>					2. Issuer Name and Ticker or Trading Symbol <u>Minerva Neurosciences</u> , <u>Inc.</u> [NERV]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O WF	(Last) (First) (Middle) C/O WFD VENTURES LLC				3. Date of Earliest Transaction (Month/Day/Year) 06/11/2020							Officer (give title Other (specify below) below)				
1500 BROADWAY, 17TH FLOOR				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) NEW YORK NY 10036												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)														
		Tab	ole I - Non-D	erivati	ve Se	curities	s Ac	quired, Di	isposed o	of, or Be	neficial	ly Owned				
Date				Transactio ite onth/Day/	Year)	2A. Deemed Execution Date if any (Month/Day/Yea		Code (Ins				4 and Securities Beneficially Owned Follo		Form (D) o	r Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V	Amount	(A) oi (D)	Price	Price Reported Transaction (Instr. 3 and				
		7	Table II - De (e.e					uired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable								
Stock Option (right to buy) ⁽¹⁾	\$3.4	06/11/2020		A		40,000		(2)	06/10/2030	Common Stock	40,000	\$0.00	40,00	0	D	

Explanation of Responses:

1. This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock was granted to the Reporting Person at the discretion of the Company's board of directors for such Reporting Person's service as lead independent director.

2. The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2020 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

Remarks:

/s/ Devin Smith, Attorney-in-Fact 0

06/12/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.